This is a pilot feasibility study to determine whether fecal microbiota transplantation (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ transplant recipients with a history of one or more MDRO infections.~Study participants who meet inclusion/exclusion criteria and provide written, informed consent will provide a pre-FMT stool sample. Participants will be followed from the time of enrollment up to 3 months post FMT.~Specific organisms of interest that will be tested for by the stool cultures include vancomycin resistant enterococcus, carbapenem resistant Enterobacteriaceae and carbapenem resistant Pseudomonas. Eligible patients who demonstrate colonization with a positive culture for a specific organism of interest will be given FMT.~One FMT dose of a retention rectal enema (OpenBiome) will be administered by a nurse and supervised by our principal investigator and/or sub-investigators trained in performance of FMT.~Stool samples of study participants will be collected and analyzed as follows:~Pre-FMT: Stool collection & storage in glycerol/flash frozen, to be shipped in dry ice~48 hours post FMT: Stool collection using RNA later kit provided by OpenBiome (in hospital)~Day 7: Stool collection & storage in glycerol/flash frozen, to be shipped in dry ice~Day 14: Stool collection using RNAlater kit (at home)~Day 30: Stool collection & storage in glycerol/flash frozen (in hospital or clinic), to be shipped in dry ice~Day 90: follow-up visit in clinic, final sample collected using RNAlater kit
This is a pilot feasibility study to determine whether fecal microbiota transplantation (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ transplant recipients with a history of one or more MDRO infections.